

Natasha K Martin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1602159/publications.pdf>

Version: 2024-02-01

109
papers

7,131
citations

125106

35
h-index

68831

81
g-index

109
all docs

109
docs citations

109
times ranked

8814
citing authors

#	ARTICLE	IF	CITATIONS
1	Articulating the Trauma-Informed Theory of Individual Health Behavior. <i>Stress and Health</i> , 2022, 38, 154-162.	1.4	11
2	Modeling the population-level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia. <i>Addiction</i> , 2022, 117, 1338-1352.	1.7	11
3	The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet, The</i> , 2022, 399, 61-116.	6.3	257
4	The contribution of unstable housing to HIV and hepatitis C virus transmission among people who inject drugs globally, regionally, and at country level: a modelling study. <i>Lancet Public Health, The</i> , 2022, 7, e136-e145.	4.7	14
5	Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHO. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 353-366.	3.7	10
6	Sustained Impact of the Coronavirus Disease 2019 Pandemic on Hepatitis C Virus Treatment Initiations in the United States. <i>Clinical Infectious Diseases</i> , 2022, 75, e955-e961.	2.9	14
7	Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The STOp-C Study. <i>Clinical Infectious Diseases</i> , 2022, 75, 1809-1819.	2.9	11
8	A gender lens is needed in hepatitis C elimination research. <i>International Journal of Drug Policy</i> , 2022, 103, 103654.	1.6	10
9	Fatal overdose: Predicting to prevent. <i>International Journal of Drug Policy</i> , 2022, 104, 103677.	1.6	8
10	Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysis. <i>PLoS ONE</i> , 2022, 17, e0267853.	1.1	2
11	Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States. <i>Clinical Infectious Diseases</i> , 2021, 73, e3355-e3357.	2.9	10
12	Is hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis. <i>International Journal of Drug Policy</i> , 2021, 88, 102710.	1.6	7
13	The use of mathematical modeling to inform drug policy making. <i>International Journal of Drug Policy</i> , 2021, 88, 102759.	1.6	0
14	What is required for achieving hepatitis C virus elimination in Singapore? A modeling study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1110-1117.	1.4	3
15	Cost-effectiveness of using hepatitis C viremic hearts for transplantation into HCV-negative recipients. <i>American Journal of Transplantation</i> , 2021, 21, 657-668.	2.6	8
16	Cost and cost-effectiveness of a real-world HCV treatment program among HIV-infected individuals in Myanmar. <i>BMJ Global Health</i> , 2021, 6, e004181.	2.0	4
17	Cost-effectiveness of hepatitis C virus (HCV) elimination strategies among people who inject drugs (PWID) in Tijuana, Mexico. <i>Addiction</i> , 2021, 116, 2734-2745.	1.7	4
18	Impact of cumulative incarceration and the post-release period on syringe-sharing among people who inject drugs in Tijuana, Mexico: a longitudinal analysis. <i>Addiction</i> , 2021, 116, 2724-2733.	1.7	4

#	ARTICLE	IF	CITATIONS
19	The cost-effectiveness of case-finding strategies for achieving hepatitis C elimination among men who have sex with men in the UK. <i>Journal of Viral Hepatitis</i> , 2021, 28, 897-908.	1.0	3
20	Discussion of article by Ellenberg and Morris. <i>Statistics in Medicine</i> , 2021, 40, 2511-2512.	0.8	0
21	The estimated hepatitis C seroprevalence and key population sizes in San Diego in 2018. <i>PLoS ONE</i> , 2021, 16, e0251635.	1.1	3
22	Overlapping Key Populations and HIV Transmission in Tijuana, Mexico: A Modelling Analysis of Epidemic Drivers. <i>AIDS and Behavior</i> , 2021, 25, 3814-3827.	1.4	7
23	Rapid, Large-Scale Wastewater Surveillance and Automated Reporting System Enable Early Detection of Nearly 85% of COVID-19 Cases on a University Campus. <i>MSystems</i> , 2021, 6, e0079321.	1.7	94
24	Assessing HIV and overdose risks for people who use drugs exposed to compulsory drug abstinence programs (CDAP): A systematic review and meta-analysis. <i>International Journal of Drug Policy</i> , 2021, 96, 103401.	1.6	5
25	Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP Treatment as Prevention Study in Prisons. <i>Hepatology</i> , 2021, 74, 2366-2379.	3.6	9
26	BRIDGING THE GAP BETWEEN PILOT AND SCALE-UP. <i>Sexually Transmitted Diseases</i> , 2021, Publish Ahead of Print, 59-66.	0.8	1
27	Identifying counties at risk of high overdose mortality burden during the emerging fentanyl epidemic in the USA: a predictive statistical modelling study. <i>Lancet Public Health</i> , The, 2021, 6, e720-e728.	4.7	22
28	What the HIV Pandemic Experience Can Teach the United States About the COVID-19 Response. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 1-10.	0.9	10
29	Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission Mitigation Strategies on a University Campus Using an Agent-Based Network Model. <i>Clinical Infectious Diseases</i> , 2021, 73, 1735-1741.	2.9	29
30	Estimating vaccination threshold and impact in the 2017-2019 hepatitis A virus outbreak among persons experiencing homelessness or who use drugs in Louisville, Kentucky, United States. <i>Vaccine</i> , 2021, 39, 7182-7190.	1.7	7
31	Screening for Sexually Transmitted Infections During Hepatitis C Treatment to Predict Reinfection Among People With HIV. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa643.	0.4	1
32	Safe reopening of college campuses during COVID-19: The University of California experience in Fall 2020. <i>PLoS ONE</i> , 2021, 16, e0258738.	1.1	21
33	Prevalence and correlates of SARS-CoV-2 seropositivity among people who inject drugs in the San Diego-Tijuana border region. <i>PLoS ONE</i> , 2021, 16, e0260286.	1.1	35
34	Interim effect evaluation of the hepatitis C elimination programme in Georgia: a modelling study. <i>The Lancet Global Health</i> , 2020, 8, e244-e253.	2.9	16
35	Scaling up screening and treatment for elimination of hepatitis C among men who have sex with men in the era of HIV pre-exposure prophylaxis. <i>EClinicalMedicine</i> , 2020, 19, 100217.	3.2	13
36	Estimating the contribution of stimulant injection to HIV and HCV epidemics among people who inject drugs and implications for harm reduction: A modeling analysis. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108135.	1.6	20

#	ARTICLE	IF	CITATIONS
37	Modelling integrated antiretroviral treatment and harm reduction services on HIV and overdose among people who inject drugs in Tijuana, Mexico. <i>Journal of the International AIDS Society</i> , 2020, 23, e25493.	1.2	11
38	Integrating HIV pre-exposure prophylaxis and harm reduction among men who have sex with men and transgender women to address intersecting harms associated with stimulant use: a modelling study. <i>Journal of the International AIDS Society</i> , 2020, 23, e25495.	1.2	14
39	What is needed to achieve HCV microelimination among HIV-infected populations in Andalusia, Spain: a modeling analysis. <i>BMC Infectious Diseases</i> , 2020, 20, 588.	1.3	2
40	Prisons can also improve drug user health in the community. <i>Addiction</i> , 2020, 115, 914-915.	1.7	0
41	Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysis. <i>The Lancet Global Health</i> , 2020, 8, e440-e450.	2.9	25
42	Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England. <i>Addiction</i> , 2020, 115, 1509-1521.	1.7	8
43	Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1388-1403.	1.0	11
44	Eliminating Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men in Berlin: A Modeling Analysis. <i>Journal of Infectious Diseases</i> , 2019, 220, 1635-1644.	1.9	24
45	Chronic hepatitis B virus case-finding in UK populations born abroad in intermediate or high endemicity countries: an economic evaluation. <i>BMJ Open</i> , 2019, 9, e030183.	0.8	9
46	Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) – a natural experiment (protocol). <i>BMJ Open</i> , 2019, 9, e029538.	0.8	30
47	Responding to global stimulant use: challenges and opportunities. <i>Lancet, The</i> , 2019, 394, 1652-1667.	6.3	169
48	Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States. <i>Clinical Infectious Diseases</i> , 2019, 69, 1888-1895.	2.9	61
49	Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection. <i>PLoS ONE</i> , 2019, 14, e0217964.	1.1	14
50	Scaling Up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States: A Rural and Urban Comparison. <i>American Journal of Epidemiology</i> , 2019, 188, 1539-1551.	1.6	29
51	Primary Incidence of Hepatitis C Virus Infection Among HIV-Infected Men Who Have Sex With Men in San Diego, 2000–2015. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz160.	0.4	24
52	The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 435-444.	3.7	145
53	Evaluating the impact of global fund withdrawal on needle and syringe provision, cost and use among people who inject drugs in Tijuana, Mexico: a costing analysis. <i>BMJ Open</i> , 2019, 9, e026298.	0.8	13
54	Opioid agonist treatment scale-up and the initiation of injection drug use: A dynamic modeling analysis. <i>PLoS Medicine</i> , 2019, 16, e1002973.	3.9	17

#	ARTICLE	IF	CITATIONS
55	Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. <i>Liver International</i> , 2019, 39, 20-30.	1.9	88
56	Hepatitis case finding among migrants in primary care. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 3-4.	3.7	4
57	Mathematical modeling of hepatitis c virus (HCV) prevention among people who inject drugs: A review of the literature and insights for elimination strategies. <i>Journal of Theoretical Biology</i> , 2019, 481, 194-201.	0.8	38
58	Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. <i>Journal of Hepatology</i> , 2018, 68, 402-411.	1.8	105
59	Is hepatitis C virus elimination possible among people living with <scp>HIV</scp> and what will it take to achieve it?. <i>Journal of the International AIDS Society</i> , 2018, 21, e25062.	1.2	39
60	Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination. <i>International Journal of Epidemiology</i> , 2018, 47, 550-560.	0.9	64
61	Scalingâ€”up HCV prevention and treatment interventions in rural United Statesâ€”model projections for tackling an increasing epidemic. <i>Addiction</i> , 2018, 113, 173-182.	1.7	71
62	The effect of public health-oriented drug law reform on HIV incidence in people who inject drugs in Tijuana, Mexico: an epidemic modelling study. <i>Lancet Public Health</i> , The, 2018, 3, e429-e437.	4.7	33
63	Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1397-1409.	4.6	147
64	Understanding and Addressing Hepatitis C Virus Reinfection Among Men Who Have Sex with Men. <i>Infectious Disease Clinics of North America</i> , 2018, 32, 395-405.	1.9	15
65	Modelling the impact of a national scaleâ€”up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland. <i>Addiction</i> , 2018, 113, 2118-2131.	1.7	15
66	Impact of current and scaledâ€”up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settingsâ€”what is required to achieve the WHO's HCV elimination targets?. <i>Addiction</i> , 2018, 113, 1727-1738.	1.7	30
67	Potential impact of implementing and scaling up harm reduction and antiretroviral therapy on HIV prevalence and mortality and overdose deaths among people who inject drugs in two Russian cities: a modelling study. <i>Lancet HIV</i> ,the, 2018, 5, e578-e587.	2.1	29
68	Cost of provision of opioid substitution therapy provision in Tijuana, Mexico. <i>Harm Reduction Journal</i> , 2018, 15, 28.	1.3	20
69	Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Societyâ€”Lancet Commission. <i>Lancet</i> , The, 2018, 392, 312-358.	6.3	230
70	Hepatitis C virus prevention and treatment prioritizationâ€”ethical, economic and evidential dimensions of early rather than delayed treatment for people who inject drugs. <i>Addiction</i> , 2017, 112, 201-203.	1.7	6
71	Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. <i>Addiction</i> , 2017, 112, 1302-1314.	1.7	80
72	Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?. <i>Addiction</i> , 2017, 112, 1290-1299.	1.7	42

#	ARTICLE	IF	CITATIONS
73	Behavioural, not biological, factors drive the HCV epidemic among HIV-positive MSM: HCV and HIV modelling analysis including HCV treatment-as-prevention impact. <i>International Journal of Epidemiology</i> , 2017, 46, 1582-1592.	0.9	25
74	How to eliminate HCV infection by antiviral treatment. <i>Journal of Hepatology</i> , 2017, 67, 5-6.	1.8	16
75	Hepatitis C Virus (HCV) Treatment as Prevention: Epidemic and Cost-Effectiveness Modeling. <i>Handbook of Statistics</i> , 2017, 37, 93-119.	0.4	0
76	Modeling Combination HCV Prevention among HIV-infected Men Who Have Sex With Men and People Who Inject Drugs. <i>AIDS Reviews</i> , 2017, 19, 97-104.	0.5	4
77	The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2016, 388, 1081-1088.	6.3	1,080
78	HIV treatment as prevention among people who inject drugs – a re-evaluation of the evidence. <i>International Journal of Epidemiology</i> , 2016, 46, dyw180.	0.9	19
79	Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis. <i>Hepatology</i> , 2016, 63, 1796-1808.	3.6	58
80	Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? <i>Epidemiological and Modeling Insights. Clinical Infectious Diseases</i> , 2016, 62, 1072-1080.	2.9	122
81	Overlapping substance using high-risk groups and infectious diseases: how dynamic modelling can evaluate risk and target HIV prevention. <i>Addiction</i> , 2016, 111, 1512-1515.	1.7	7
82	The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. <i>Lancet, The</i> , 2016, 388, 1228-1248.	6.3	213
83	Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. <i>BMJ, The</i> , 2016, 355, i5170.	3.0	415
84	Reply. <i>Hepatology</i> , 2016, 64, 1822-1823.	3.6	0
85	Public health and international drug policy. <i>Lancet, The</i> , 2016, 387, 1427-1480.	6.3	460
86	Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. <i>Journal of Hepatology</i> , 2016, 65, 17-25.	1.8	157
87	The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?. <i>PLoS ONE</i> , 2016, 11, e0156213.	1.1	41
88	HCV treatment as prevention in prison: Key issues. <i>Hepatology</i> , 2015, 61, 402-403.	3.6	12
89	The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and) <i>Tj ETQq1 1 0.784314 rgBT /Over</i>	1.5	119
90	Cost-Effectiveness of HBV and HCV Screening Strategies – A Systematic Review of Existing Modelling Techniques. <i>PLoS ONE</i> , 2015, 10, e0145022.	1.1	32

#	ARTICLE	IF	CITATIONS
91	STI/HIV test result disclosure between female sex workers and their primary, non-commercial male partners in two Mexico-US border cities: a prospective study. <i>Sexually Transmitted Infections</i> , 2015, 91, 207-213.	0.8	3
92	The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments. <i>BMC Medicine</i> , 2015, 13, 198.	2.3	54
93	Glucose-lactate metabolic cooperation in cancer: Insights from a spatial mathematical model and implications for targeted therapy. <i>Journal of Theoretical Biology</i> , 2014, 361, 190-203.	0.8	18
94	Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. <i>The Lancet Global Health</i> , 2014, 2, e23-e34.	2.9	188
95	Modeling the impact of early antiretroviral therapy for adults coinfecting with HIV and hepatitis B or C in South Africa. <i>Aids</i> , 2014, 28, S35-S46.	1.0	23
96	Optimal Allocation of Resources in Female Sex Worker Targeted HIV Prevention Interventions: Model Insights from Avahan in South India. <i>PLoS ONE</i> , 2014, 9, e107066.	1.1	9
97	How cost-effective is hepatitis C virus treatment for people who inject drugs?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 590-592.	1.4	10
98	Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission?. <i>Drug and Alcohol Dependence</i> , 2013, 132, 172-181.	1.6	40
99	Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. <i>BMJ Open</i> , 2013, 3, e003153.	0.8	74
100	Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy. <i>Clinical Infectious Diseases</i> , 2013, 57, S39-S45.	2.9	275
101	Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. <i>Hepatology</i> , 2013, 58, 1598-1609.	3.6	431
102	Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. <i>Aids</i> , 2013, 27, 2551-2557.	1.0	152
103	Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings-Implications for intervention impact. <i>Drug and Alcohol Dependence</i> , 2012, 123, 122-131.	1.6	34
104	Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. <i>Medical Journal of Australia</i> , 2012, 196, 638-641.	0.8	51
105	Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. <i>Addiction</i> , 2012, 107, 1984-1995.	1.7	128
106	Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. <i>Hepatology</i> , 2012, 55, 49-57.	3.6	194
107	Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. <i>Journal of Hepatology</i> , 2011, 54, 1137-1144.	1.8	199
108	Optimal Control of Hepatitis C Antiviral Treatment Programme Delivery for Prevention amongst a Population of Injecting Drug Users. <i>PLoS ONE</i> , 2011, 6, e22309.	1.1	36

#	ARTICLE	IF	CITATIONS
109	Mathematical modelling of hepatitis C treatment for injecting drug users. Journal of Theoretical Biology, 2011, 274, 58-66.	0.8	86